Filing identity and reporting period
Important discrepancy: The request identifies Lite Strategy, Inc. and 2011 Q2, but the supplied filing is MEI Pharma, Inc.’s Form 10-Q for the six months ended December 31, 2012, including the quarter ended that date. The summary below reflects the supplied filing.
MEI Pharma is a development-stage oncology company focused on Pracinostat, ME-143, and ME-344. Financial statement amounts below are in millions of dollars unless noted; share and per-share information reflects the 1-for-6 reverse split.
Financial performance and position
| Metric | Three months ended Dec. 31, 2012 | Six months ended Dec. 31, 2012 | Comparable 2011 period |
|---|---|---|---|
| Revenue | No revenue amount is reported in the supplied statements. | No revenue amount is reported. | |
| Research and development expense | $1.338 | $2.890 | $1.061 quarter; $2.105 six months |
| General and administrative expense | $1.418 | $2.332 | $0.896 quarter; $1.785 six months |
| Total operating expenses / operating loss | $2.756 | $5.222 | $1.957 quarter; $3.890 six months |
| Net loss | $2.754 | $5.218 | $1.541 quarter; $3.153 six months |
| Basic and diluted loss per share | $(0.50) | $(1.17) | $(0.78) quarter; $(1.76) six months |
There is no meaningful gross margin information because the filing does not report revenue. Cash and cash equivalents were $26.877 million at December 31, 2012, versus $6.202 million at June 30, 2012. Total assets were $27.584 million; current liabilities were $1.797 million, primarily accounts payable and accrued liabilities. The balance sheet reports no debt balance.
For the six months, operating cash use was $4.647 million, investing cash use was $0.004 million, and financing provided $25.326 million. Cash increased by $20.675 million. Accumulated development-stage losses were $90.329 million. Management expects continuing operating losses and negative operating cash flows for the foreseeable future.
Material changes versus prior comparable periods
- Six-month net loss increased to $5.218 million from $3.153 million; quarterly net loss increased to $2.754 million from $1.541 million.
- Six-month R&D expense rose $0.785 million, principally due to Phase I trial and drug-manufacturing costs for ME-143 and ME-344. Quarterly R&D rose $0.277 million for similar reasons.
- Six-month G&A increased $0.547 million, reflecting legal and other costs related to the Pracinostat acquisition, professional and consulting fees, and share-based compensation.
- Cash rose substantially following the December 2012 private placement. The company sold 9,166,665 shares and warrants for an aggregate offering price of $27.5 million; reported net financing proceeds for the six-month period were $25.326 million.
- Novogen distributed substantially all of its MEI Pharma shares to its shareholders in December 2012, ending its position as majority shareholder. The company also acquired Pracinostat-related assets from S*BIO in August 2012, issuing $0.5 million of common stock consideration.
Outlook, risks, contingencies, and unusual items
- Management expected to initiate a randomized, placebo-controlled Phase II trial of Pracinostat with azacitidine in myelodysplastic syndrome in the second quarter of calendar 2013. An intravenous ME-344 Phase I trial was ongoing; the filing describes prior Phase I results for intravenous ME-143.
- The S*BIO agreement provides for potential clinical, regulatory, and sales milestone payments of up to $75.2 million, plus contingent earn-out payments based on net sales. The filing does not quantify potential CyDex license milestones or royalties.
- Clinical-development contracts are terminable but require reimbursement for work and costs incurred. Certain employment agreements provide possible severance and accelerated equity-award vesting. The office lease was extended through June 2015, with additional space and rent of $17,014–$18,252 per month once the amended terms take effect.
- Key risks include the need for future financing, clinical-trial uncertainty and delays, regulatory approval, commercialization, manufacturing costs, competition, and intellectual-property rights. The company may seek additional equity financing or strategic partnerships; no specific financial guidance is provided.
- MEI received a Nasdaq minimum-bid-price deficiency notice in 2012 but reported regaining compliance on November 26, 2012. The filing reports effective disclosure controls and no material change in internal control over financial reporting during the quarter.
- Interest-rate movements were not considered a material risk. Cash is held primarily in U.S. dollars, including deposits exceeding federally insured limits; management stated it believed credit risk was not significant.
Important facts for investors to verify
- Confirm the filing identity and period: the supplied document is MEI Pharma’s December 31, 2012 Form 10-Q, not a Lite Strategy, Inc. 2011 Q2 filing.
- Review the trial status, expected timing, and subsequent results for Pracinostat, ME-143, and ME-344, including the planned Pracinostat Phase II study.
- Assess cash burn and funding needs against the $26.877 million cash balance, while recognizing management expected continuing losses and negative operating cash flow.
- Review dilution and potential proceeds or obligations from the private-placement warrants, outstanding options, and up to $75.2 million of S*BIO milestones plus sales-based earn-outs.
- Check subsequent SEC filings for changes to Nasdaq listing status, material clinical or regulatory developments, financing, and the terms or payments under the CyDex agreements.